Compare BioNano Genomics Inc (BNGO) vs Dollar General Corp. (DG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BioNano Genomics Inc vs Dollar General Corp. — how do they compare? BioNano Genomics Inc trades at $1.18 (market cap $13.20M), while Dollar General Corp. trades at $121.41 (market cap $26.50B). The key difference: Dollar General Corp. is far larger — about 2007.6× BioNano Genomics Inc's market cap, and Dollar General Corp. pays a 1.96% dividend while BioNano Genomics Inc pays none. Which is the better fit depends on your goals.
| BNGO | DG | |
|---|---|---|
Market Cap | $13.20M | $26.50B |
Sector | Health | Consumer Staples |
52-Week High | $4.92 | $156.26 |
52-Week Low | $1.09 | $95.94 |
Enterprise Value | $15.81M | $40.95B |
Dividend Yield | — | 1.96% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Bionano Genomics (BNGO) trades at $1.17, down 2.5% today, but maintains a bullish technical signal with strong moving average support. The company shows improving fundamentals with revenue stabilizing around $29M annually and narrowing losses, though it remains unprofitable with a -109.95% net margin. Recent positive developments include debt retirement and growing adoption of optical genome mapping technology.
BNGO presents a high-risk, high-reward opportunity with analyst consensus leaning bullish (57% buy ratings). The stock trades at attractive valuation multiples (P/S 0.31, P/B 0.36) but faces execution risks in achieving profitability. Key catalysts include continued technology adoption and potential margin improvement, while persistent losses and competitive pressures remain concerns.
Dollar General (DG) trades at $123.44, up 3.8% with strong technical momentum and bullish analyst sentiment. The stock shows consistent earnings beats, with Q1 2026 EPS of $2.00 exceeding expectations of $1.89. Revenue growth continues at $40.61B for 2025, while profit margins face pressure at 3.63%. Recent news highlights the company's back-to-school initiatives and margin expansion efforts.
The outlook remains positive with a $128.45 consensus price target representing 4% upside. Key opportunities include continued same-store sales growth and margin recovery, while risks involve consumer spending sensitivity and competitive pressures in discount retail. The technical setup suggests near-term resistance around $125-$128 levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About BioNano Genomics Inc
Bionano Genomics Inc is a life sciences instrumentation company in the genome analysis space. It is engaged in the development and marketing of the Saphyr system, a platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets and to streamline the study of changes in chromosomes.
Read more on BNGO →About Dollar General Corp.
A leading American discount retailer, Dollar General operates over 18,000 stores in 47 states, selling branded and private-label products across a wide variety of categories. In fiscal 2021, 77% of net sales came from consumables (including paper and cleaning products, packaged and perishable food, tobacco, and health and beauty items), 12% from seasonal merchandise (such as toys, greeting cards, decorations, and gardening supplies), 7% from home products (for example, kitchen supplies, small appliances, and cookware), and 4% from basic apparel. Stores average roughly 7,400 square feet, and about 75% of Dollar General locations are in towns of 20,000 or fewer people. The firm emphasizes value, with most of its items sold at everyday low prices of $5 or less.
Read more on DG →
